Democratic senators call for $26B in next COVID-19 relief package to support research workforce

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Senators Edward J. Markey (D-MA) and Thom Tillis (R-NC) and 31 of their Senate colleagues are calling for protections for the U.S. scientific research community during the coronavirus pandemic.

Although novel coronavirus-related research is a current federal government priority, most other research has slowed or stopped due to closures of campuses and laboratories. The people who comprise the research workforce—graduate students, postdocs, principal investigators, and technical support staff—face financial and other hardships from the disruption of their research activities.

The senators are calling for $26 billion in emergency relief funding for the research community in the next coronavirus relief package.

“Research universities, academic medical centers, and national labs are major employers in all 50 states, and protecting the research workforce is critical to state economies,” wrote the senators in their letter to Senate leadership. “Congress must act to preserve our current scientific workforce and ensure that the U.S. is prepared to continue our global scientific leadership once this crisis ends.”

In their letter, the senators specifically call for funding in the next relief package to:

  • Cover supplements for research grants and contracts caused by the pandemic, including additional salary support and/or research related ramp-up costs;

  • Provide emergency relief to sustain research support personnel and base operating costs for core research facilities and user-funded research services until such time as facilities reopen and research activities return to pre-pandemic activity levels; and

  • Fund additional graduate student and postdoc fellowships, traineeships, and research assistantships for up to two years. Graduate students who could not complete their degrees due to the pandemic should be given priority for graduate fellowships and other forms of support so they can complete their research and degrees.

This effort has been endorsed by the Association of American Universities, American Council on Education, Association of Public and Land-grant Universities, Association of American Medical Colleges, Union of Concerned Scientists, ACT for NIH, Alzheimer’s Association, American Association for Cancer Research, American Cancer Society Cancer Action Network, American Geophysical Union, American Lung Association, American Mathematical Society, American Meteorological Society, American Chemical Society, American Physical Society, American Physiological Society, American Society for Cell Biology, American Society for Microbiology, Association of Independent Research Institutes, Autism Speaks, Coalition for the Life Sciences, EveryLife Foundation for Rare Diseases, Friends of Cancer Research, Geological Society of America , JDRF, Research!America, Society for Neuroscience, and other groups.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login